258 related articles for article (PubMed ID: 25316809)
1. The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer.
Fang F; Munck J; Tang J; Taverna P; Wang Y; Miller DF; Pilrose J; Choy G; Azab M; Pawelczak KS; VanderVere-Carozza P; Wagner M; Lyons J; Matei D; Turchi JJ; Nephew KP
Clin Cancer Res; 2014 Dec; 20(24):6504-16. PubMed ID: 25316809
[TBL] [Abstract][Full Text] [Related]
2. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling.
Zeller C; Dai W; Steele NL; Siddiq A; Walley AJ; Wilhelm-Benartzi CS; Rizzo S; van der Zee A; Plumb JA; Brown R
Oncogene; 2012 Oct; 31(42):4567-76. PubMed ID: 22249249
[TBL] [Abstract][Full Text] [Related]
3. Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo.
Steele N; Finn P; Brown R; Plumb JA
Br J Cancer; 2009 Mar; 100(5):758-63. PubMed ID: 19259094
[TBL] [Abstract][Full Text] [Related]
4. Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts.
Srivastava P; Paluch BE; Matsuzaki J; James SR; Collamat-Lai G; Taverna P; Karpf AR; Griffiths EA
Epigenetics; 2015; 10(3):237-46. PubMed ID: 25793777
[TBL] [Abstract][Full Text] [Related]
5. DNA Methylation of miR-7 is a Mechanism Involved in Platinum Response through
Vera O; Jimenez J; Pernia O; Rodriguez-Antolin C; Rodriguez C; Sanchez Cabo F; Soto J; Rosas R; Lopez-Magallon S; Esteban Rodriguez I; Dopazo A; Rojo F; Belda C; Alvarez R; Valentin J; Benitez J; Perona R; De Castro J; Ibanez de Caceres I
Theranostics; 2017; 7(17):4118-4134. PubMed ID: 29158814
[TBL] [Abstract][Full Text] [Related]
6. Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabine.
Albany C; Hever-Jardine MP; von Herrmann KM; Yim CY; Tam J; Warzecha JM; Shin L; Bock SE; Curran BS; Chaudhry AS; Kim F; Sandusky GE; Taverna P; Freemantle SJ; Christensen BC; Einhorn LH; Spinella MJ
Oncotarget; 2017 Jan; 8(2):2949-2959. PubMed ID: 27936464
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic targeting of ovarian cancer stem cells.
Wang Y; Cardenas H; Fang F; Condello S; Taverna P; Segar M; Liu Y; Nephew KP; Matei D
Cancer Res; 2014 Sep; 74(17):4922-36. PubMed ID: 25035395
[TBL] [Abstract][Full Text] [Related]
8. Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer.
Balch C; Yan P; Craft T; Young S; Skalnik DG; Huang TH; Nephew KP
Mol Cancer Ther; 2005 Oct; 4(10):1505-14. PubMed ID: 16227399
[TBL] [Abstract][Full Text] [Related]
9. Transmembrane protein 88 (TMEM88) promoter hypomethylation is associated with platinum resistance in ovarian cancer.
de Leon M; Cardenas H; Vieth E; Emerson R; Segar M; Liu Y; Nephew K; Matei D
Gynecol Oncol; 2016 Sep; 142(3):539-47. PubMed ID: 27374141
[TBL] [Abstract][Full Text] [Related]
10. Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways.
Tomar T; de Jong S; Alkema NG; Hoekman RL; Meersma GJ; Klip HG; van der Zee AG; Wisman GB
Genome Med; 2016 Oct; 8(1):107. PubMed ID: 27765068
[TBL] [Abstract][Full Text] [Related]
11. [Effects of 5-Aza-2'-deoxycytidine and trichostatin A on DNA methylation and expression of hMLH1 in ovarian cancer cell line COC1/DDP].
Meng CF; Dai DQ; Guo KJ
Ai Zheng; 2008 Dec; 27(12):1251-5. PubMed ID: 19079988
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo.
Hu S; Yu L; Li Z; Shen Y; Wang J; Cai J; Xiao L; Wang Z
Cancer Biol Ther; 2010 Oct; 10(8):788-95. PubMed ID: 20686362
[TBL] [Abstract][Full Text] [Related]
13. Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter.
Plumb JA; Strathdee G; Sludden J; Kaye SB; Brown R
Cancer Res; 2000 Nov; 60(21):6039-44. PubMed ID: 11085525
[TBL] [Abstract][Full Text] [Related]
14. TGF-β induces global changes in DNA methylation during the epithelial-to-mesenchymal transition in ovarian cancer cells.
Cardenas H; Vieth E; Lee J; Segar M; Liu Y; Nephew KP; Matei D
Epigenetics; 2014 Nov; 9(11):1461-72. PubMed ID: 25470663
[TBL] [Abstract][Full Text] [Related]
15. Hypermethylation of mismatch repair gene hMSH2 associates with platinum-resistant disease in epithelial ovarian cancer.
Tian H; Yan L; Xiao-Fei L; Hai-Yan S; Juan C; Shan K
Clin Epigenetics; 2019 Oct; 11(1):153. PubMed ID: 31666131
[TBL] [Abstract][Full Text] [Related]
16. Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo.
Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M
Cell Physiol Biochem; 2016; 39(1):242-52. PubMed ID: 27336949
[TBL] [Abstract][Full Text] [Related]
17. Platinum-Based Chemotherapy Induces Methylation Changes in Blood DNA Associated with Overall Survival in Patients with Ovarian Cancer.
Flanagan JM; Wilson A; Koo C; Masrour N; Gallon J; Loomis E; Flower K; Wilhelm-Benartzi C; Hergovich A; Cunnea P; Gabra H; Braicu EI; Sehouli J; Darb-Esfahani S; Vanderstichele A; Vergote I; Kreuzinger C; Castillo-Tong DC; Wisman GBA; Berns EM; Siddiqui N; Paul J; Brown R
Clin Cancer Res; 2017 May; 23(9):2213-2222. PubMed ID: 27663594
[No Abstract] [Full Text] [Related]
18. Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells.
Abbosh PH; Montgomery JS; Starkey JA; Novotny M; Zuhowski EG; Egorin MJ; Moseman AP; Golas A; Brannon KM; Balch C; Huang TH; Nephew KP
Cancer Res; 2006 Jun; 66(11):5582-91. PubMed ID: 16740693
[TBL] [Abstract][Full Text] [Related]
19. The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation.
Wang H; Fang L; Jiang J; Kuang Y; Wang B; Shang X; Han P; Li Y; Liu M; Zhang Z; Li P
Cell Death Dis; 2018 Oct; 9(11):1103. PubMed ID: 30375398
[TBL] [Abstract][Full Text] [Related]
20. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer.
Strathdee G; MacKean MJ; Illand M; Brown R
Oncogene; 1999 Apr; 18(14):2335-41. PubMed ID: 10327053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]